Gazi Yasargil Training and Research Hospital, located in Diyarbakır province in southeastern Turkey, was designed as a pandemic hospital from the beginning of the coronavirus disease-2019 (COVID-19) outbreak. The first cases in this region were seen on March 22, 2020. In this study, it is aimed to retrospectively examine critical patients admitted to the intensive care unit (ICU) due to COVID-19 from the first onset of cases until September 01, 2020 and to examine the factors affecting mortality. The necessary permits for the study were obtained from the Scientific Research Platform of the T.R. Ministry of Health and the Ethics Committee of the Gazi Yasargil educational and Research Hospital in Diyarbakır. (No: 550, 11.09.2020) Patients diagnosed with COVID-19 on the specified dates, followed in the ICU, older than 18 years, identified as critical/serious according to the World Health Organization and provisional guidelines of the Scientific Board of the T.R. Ministry of Health will be included in the study. ICU patients without COVID-19; COVID-19 patients under 18 years of age; COVID-19 patients with mild to moderate symptoms, no respiratory distress, no signs of common pneumonia on lung radiography or tomography will be excluded from the study. Patients' age, gender, comorbidity, Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA) and Kidney Disease: Improving Global Outcomes (KDIGO) scores when first admitted to the ICU, hemogram parameters (white blood cell count, neutrophil, lymphocyte, neutrophil / lymphocyte ratio, hemoglobin, hematocrit, platelet count), blood gas information (pH, Partial oxygen pressure-PO2, Partial pressure of carbon dioxide-PCO2, bicarbonate-HCO3, lactate), coagulation parameters (prothrombin time and D-dimer, blood biochemistry results (C-reactive protein, lactate dehydrogenase, creatine kinase , urea, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin and indirect bilirubin), procalcitonin and ferritin levels will be recorded. In addition, the number of days spent in the ICU and whether mortality develops or not will be recorded. Patients will be divided into two groups according to their clinical results as those without mortality during ICU follow-up (Group S) and those with mortality (Group NS). The clinical characteristics of both groups, APACHE II, SOFA, KDIGO scores and laboratory results at the first admission to the ICU will be compared. With the diagnosis of COVID-19, factors affecting mortality in critical patients in the ICU will be tried to be determined.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Acute Physiology and Chronic Health Evaluation II Score
Timeframe: APACHE II score on the first admission of ICU
Sequential Organ Failure Assessment Score
Timeframe: SOFA score on the first admission of ICU
Kidney Disease: Improving Global Outcomes Scores
Timeframe: When the patients were admitted to ICU for the first time.
White Blood Cell
Timeframe: At ICU admission
Neutrophil
Timeframe: When the patients were admitted to ICU for the first time
Lymphocyte
Timeframe: When the patients were admitted to ICU for the first time
Neutrophil Lymphocyte Ratio
Timeframe: the first admission to ICU
Comorbidities
Timeframe: When the patients were admitted to ICU for the first time
Diabetes
Timeframe: When the patients were admitted to ICU for the first time
Hypertension
Timeframe: When the patients were admitted to ICU for the first time
Chronic Obstructive Pulmonary Disease
Timeframe: When the patients were admitted to ICU for the first time
Chronic Kidney Disease
Timeframe: When the patients were admitted to ICU for the first time
Cardiovascular Disease
Timeframe: When the patients were admitted to ICU for the first time
Hemoglobin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Hematocrit
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Platelet
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Prothrombin Time
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
D-dimer
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Blood Gas Analysis-pH
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Partial Oxygen Pressure
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Partial Pressure of Carbon Dioxide
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Bicarbonate
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Lactate
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Lactate Dehydrogenase
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Creatine Kinase
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
C-reactive Protein
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Blood Urea Nitrogen
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Creatinine
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Alanine Aminotransferase
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Aspartate Aminotransferase
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Total Bilirubin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Direct Bilirubin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Indirect Bilirubin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Procalcitonin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)
Ferritin
Timeframe: At ICU admission (first laboratory measurement after ICU admission)